Business · 13/02/2026Updated: 10/16/2026 · 1 min read
Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases
Summary
The National Cancer Institute is considering granting an Exclusive Patent License to Kyverna Therapeutics, Inc. for the treatment or prevention of B Cell Mediated Autoimmune Diseases.